Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | TGM2 | P21980 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | AKT1 | P31749 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1936275 | 0.80 | ALDH1A1 (0.36) | ALDH1A1TSHRCYP2C19HTTAKT1 | |
| SCHEMBL8992320 | 0.76 | ALDH1A1 (0.33) | ALDH1A1TSHRCYP2C19 | |
| SCHEMBL7193217 | 0.76 | ALDH1A1 (0.33) | ALDH1A1TSHRCYP2C19 | |
| SCHEMBL7628010 | 0.70 | CALM1 (0.32) | ALDH1A1 | |
| SCHEMBL9816218 | 0.69 | CYP2C19 (0.30) | CYP2C19 | |
| SCHEMBL1477747 | 0.65 | TSHR (0.41) | ALDH1A1TSHRTGM2AKT1 | |
| SCHEMBL5881431 | 0.65 | TSHR (0.41) | ALDH1A1TSHRTGM2AKT1 | |
| SCHEMBL7640554 | 0.65 | CALM1 (0.32) | ALDH1A1 | |
| SCHEMBL416584 | 0.65 | TP53 (0.41) | ALDH1A1TSHR | |
| SCHEMBL8992232 | 0.63 | CALM1 (0.43) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105073752-B | Method for producing tricyclic compound and tricyclic compound producible by the production method | 大鹏药品工业株式会社 | 2017-08-15 | — | — | CN | claimed |
| EP-1534664-A1 | N-BISARYL- AND N-ARYL-CYCLOALKYLIDENYL-ALPHA-HYDROXY-AND ALPHA-ALKOXY ACID AMIDES | Syngenta Participations AG (CH) | 2005-06-01 | — | — | EP | claimed |
| WO-2004011417-A1 | N-BISARYL- AND N-ARYL-CYCLOALKYLIDENYL-ALPHA-HYDROXY-AND ALPHA-ALKOXY ACID AMIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2004-02-05 | — | — | WO | claimed |
| US-5516871-A | Diphenylsiloxane oligomers functionalized at both terminals and methods for the preparation thereof | DOW CORNING ASIA, LTD. (JP) | 1996-05-14 | — | — | US | claimed |
| US-5502229-A | ENDCAPPING | DOW CORNING ASIA, LTD. (JP) | 1996-03-26 | — | — | US | claimed |
| US-4814347-A | ANTIBIOTIC INTERMEDIATE | THE UPJOHN COMPANY (US) | 1989-03-21 | — | — | US | claimed |
| US-4812582-A | ANTHEMINTIC INTERMEDIATES | THE UPJOHN COMPANY (US) | 1989-03-14 | — | — | US | claimed |
| US-4686297-A | Anthelmintic spiroketals useful for killing parasitic worms | THE UPJOHN COMPANY (US) | 1987-08-11 | — | — | US | claimed |
| US-4680419-A | ANTHELMINTICS | THE UPJOHN COMPANY (US) | 1987-07-14 | — | — | US | claimed |
| EP-4282416-A2 | PROCESS OF MANUFACTURE OF A COMPOUND FOR INHIBITING THE ACTIVITY OF SHP2 | Novartis AG (CH) | 2023-11-29 | — | — | EP | disclosed |
| WO-2023055682-A1 | MOISTURE CURABLE COMPOSITIONS | DOW SILICONES CORPORATION (US) | 2023-04-06 | — | — | WO | disclosed |
| US-20210346375-A1 | PROCESS OF MANUFACTURE OF A COMPOUND FOR INHIBITING THE ACTIVITY OF SHP2, AS WELL AS PRODUCTS RESULTING FROM ACID ADDITION | NOVARTIS AG (CH) | 2021-11-11 | — | — | US | disclosed |
| EP-3856345-A1 | PROCESS OF MANUFACTURE OF A COMPOUND FOR INHIBITING THE ACTIVITY OF SHP2 | Novartis AG (CH) | 2021-08-04 | — | — | EP | disclosed |
| CN-112839715-A | Method for preparing active compound for inhibiting SHP2 | 诺华股份有限公司 | 2021-05-25 | — | — | CN | disclosed |
| US-4820758-A | Novel [5.5]-spiroketals | THE UPJOHN COMPANY (US) | 1989-04-11 | — | — | US | disclosed |
| US-4814347-A | ANTIBIOTIC INTERMEDIATE | THE UPJOHN COMPANY (US) | 1989-03-21 | — | — | US | disclosed |
| US-4812582-A | ANTHEMINTIC INTERMEDIATES | THE UPJOHN COMPANY (US) | 1989-03-14 | — | — | US | disclosed |
| EP-0236510-A1 | PROSTACYCLINS AND DRUGS CONTAINING THE SAME | MITSUBISHI KASEI CORPORATION (JP) | 1987-09-16 | — | — | EP | disclosed |
| US-4686297-A | Anthelmintic spiroketals useful for killing parasitic worms | THE UPJOHN COMPANY (US) | 1987-08-11 | — | — | US | disclosed |
| US-4680419-A | ANTHELMINTICS | THE UPJOHN COMPANY (US) | 1987-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210346375-A1 | PROCESS OF MANUFACTURE OF A COMPOUND FOR INHIBITING THE ACTIVITY OF SHP2, AS WELL AS PRODUCTS RESULTING FROM ACID ADDITION | PTPN5, PTPN7, PTPN1 | ALDH1A1 3402/4885TSHR 3664/4885CYP2C19 3969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.